| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
p38α MAPK 9.6 (pIC50)
p38alpha MAPK |
|---|---|
| ln Vitro |
p38alpha inhibitor 2 is a highly potent p38alpha MAPK inhibitor with a pIC₅0 of 9.6 (IC₅0 ≈ 0.25 nM). It shows excellent selectivity when tested against 51 other protein kinase groups (<30% inhibition at 10 uM concentration) and 141 other biological target groups. It also inhibits the hERG ion channel with an IC₅0 of 27 uM, indicating a favorable selectivity margin.
|
| ln Vivo |
No detailed in vivo activity data for p38alpha inhibitor 2 has been reported. Based on its high potency and selectivity, it is expected to demonstrate robust anti‑inflammatory efficacy in animal models of inflammatory diseases at low doses (e.g., 1‑10 mg/kg). The high selectivity suggests reduced off‑target toxicity compared to less selective p38 inhibitors.
|
| Enzyme Assay |
For p38alpha enzymatic assays, recombinant p38alpha protein is incubated with p38alpha inhibitor 2 (0.01‑1000 nM) and a substrate (e.g., ATF2 or MBP) in the presence of ATP (including radiolabeled or fluorescence‑labeled ATP). After incubation (30‑60 min at 30degC), substrate phosphorylation is quantified. Alternatively, a homogeneous time‑resolved fluorescence (HTRF) kinase assay system can be used.
|
| Cell Assay |
p38alpha inhibitor 2 is dissolved in DMSO to a stock solution and diluted in cell culture media (final DMSO ≤0.1%). Cells (e.g., RAW264.7 macrophages or THP‑1 monocytes) are pre‑treated with p38alpha inhibitor 2 (0.01 nM - 10 uM) for 1 h, then stimulated with LPS (1 ug/mL) for an additional 30‑60 min. p38alpha activity is assessed by measuring phospho‑p38alpha or phospho‑ATF2 via Western blotting, or by quantifying pro‑inflammatory cytokines (e.g., IL‑6, TNF‑alpha) using ELISA.
|
| Animal Protocol |
No detailed in vivo protocol for p38alpha inhibitor 2 has been reported. Based on standard procedures for p38 inhibitors, the compound would be formulated in a suitable vehicle (e.g., 0.5% methylcellulose or 10% DMSO/40% PEG400/5% Tween 80) and administered orally or intraperitoneally to mice (doses typically 1‑30 mg/kg). Efficacy is assessed by measuring cytokine levels or inflammation scores.
|
| ADME/Pharmacokinetics |
No detailed PK data for p38alpha inhibitor 2 has been reported. As a potent, selective kinase inhibitor, it is expected to have favorable oral bioavailability and moderate plasma half‑life. The compound also shows moderate hERG inhibition (IC₅0 27 uM), suggesting low cardiotoxicity risk at therapeutic doses. Detailed parameters such as half‑life, Cmax, and clearance are not publicly available.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data for p38alpha inhibitor 2 has been reported. It shows moderate hERG inhibition with an IC₅0 of 27 uM, indicating a low risk of cardiac arrhythmias at anticipated therapeutic doses. The excellent selectivity against 51 other protein kinases (most <30% inhibition at 10 uM) suggests a favorable off‑target toxicity profile.
|
| References | |
| Additional Infomation |
p38alpha inhibitor 2 (CAS: 1095003-80-7; formula: C2₇H33N₅O3; MW: 475.58) is a highly potent and selective p38alpha MAPK inhibitor for research use only. It exhibits a pIC₅0 of 9.6 against p38alpha and shows excellent selectivity when tested against 51 other protein kinases and 141 other biological target groups. No clinical trials or regulatory approvals have been reported.
|
| Molecular Formula |
C27H33N5O3
|
|---|---|
| Molecular Weight |
475.5826
|
| Exact Mass |
475.258
|
| CAS # |
1095003-80-7
|
| PubChem CID |
25145735
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
2.7
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
35
|
| Complexity |
822
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1C([H])=C([H])C(C([H])([H])[H])=C(C=1[H])N1C([H])=C([H])N=C(C1=O)N([H])C(C([H])([H])[H])(C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1OC([H])([H])C([H])([H])N([H])C([H])([H])[H])N([H])C1([H])C([H])([H])C1([H])[H]
|
| InChi Key |
SAZVRXTVWZAHBI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C27H33N5O3/c1-18-9-10-19(25(33)30-20-11-12-20)17-22(18)32-15-13-29-24(26(32)34)31-27(2,3)21-7-5-6-8-23(21)35-16-14-28-4/h5-10,13,15,17,20,28H,11-12,14,16H2,1-4H3,(H,29,31)(H,30,33)
|
| Chemical Name |
N-cyclopropyl-4-methyl-3-[3-[2-[2-[2-(methylamino)ethoxy]phenyl]propan-2-ylamino]-2-oxopyrazin-1-yl]benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 250 mg/mL (525.67 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 6.25 mg/mL (13.14 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 62.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 6.25 mg/mL (13.14 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 62.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 6.25 mg/mL (13.14 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1027 mL | 10.5135 mL | 21.0270 mL | |
| 5 mM | 0.4205 mL | 2.1027 mL | 4.2054 mL | |
| 10 mM | 0.2103 mL | 1.0513 mL | 2.1027 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
